<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04093856</url>
  </required_header>
  <id_info>
    <org_study_id>MP-37-2020-5872</org_study_id>
    <nct_id>NCT04093856</nct_id>
  </id_info>
  <brief_title>Determinants of Bone and Muscle Quality and Strength in Obesity With and Without Diabetes</brief_title>
  <acronym>BODI2</acronym>
  <official_title>Determinants of Bone and Muscle Quality and Strength in Obesity With and Without Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Suzanne Morin</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>CHU de Quebec-Universite Laval</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>McGill University Health Centre/Research Institute of the McGill University Health Centre</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background: Osteoporotic fractures are a major public health issue. They cause substantial&#xD;
      disability, loss of autonomy, morbidity and excess mortality. Diabetes is also associated&#xD;
      with increased risk for falls and fractures through a direct impact of elevated blood glucose&#xD;
      on the skeleton and on muscles.&#xD;
&#xD;
      Research project overview: The investigators propose a cross-sectional study that will&#xD;
      involve 2 research centers in the province of Quebec. The investigators will recruit 20 obese&#xD;
      participants, without diabetes, who have not undergone bariatric surgery, for one-time&#xD;
      measurements to be compared with baseline measurements (pre-surgery) from participants in the&#xD;
      bariatric obese diabetic groups with type II diabetes mellitus from the ongoing study BODI&#xD;
      study (NCT03455868). Bone Mineral Density as well as muscle quality, strength and function&#xD;
      will be evaluated at a single study visit.&#xD;
&#xD;
      Relevance: This data will permit the evaluation of the bone-muscle unit in patients with&#xD;
      obesity with and without diabetes, and assess whether the presence and duration of diabetes&#xD;
      impacts further on clinical and functional musculoskeletal outcomes (falls, fractures and&#xD;
      mobility and strength) in this population. AGEs, if associated with muscle and bone&#xD;
      deterioration, might become an easily accessible biomarker of musculoskeletal health in the&#xD;
      clinical setting.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 14, 2020</start_date>
  <completion_date type="Actual">June 14, 2021</completion_date>
  <primary_completion_date type="Actual">June 14, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Muscle size measured as cross-sectional muscle area at the proximal femur</measure>
    <time_frame>Baseline</time_frame>
    <description>Measured by quantitative computed tomography (QCT)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Muscle composition measured as muscle fat content at the proximal femur</measure>
    <time_frame>Baseline</time_frame>
    <description>Measured by quantitative computed tomography (QCT)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Volumetric bone mineral density (vBMD) at the spine, hip, radius and tibia</measure>
    <time_frame>Baseline</time_frame>
    <description>Measured by quantitative computed tomography (QCT)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>N-terminal propeptide of type 1 procollagen concentration</measure>
    <time_frame>Baseline</time_frame>
    <description>Serum bone formation marker</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Osteocalcin (total and decarboxylated) concentration</measure>
    <time_frame>Baseline</time_frame>
    <description>Serum bone formation marker</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone specific alkaline phosphatase concentration</measure>
    <time_frame>Baseline</time_frame>
    <description>Serum bone formation marker</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C-telopeptide concentration</measure>
    <time_frame>Baseline</time_frame>
    <description>Serum bone resorption marker</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting glucose concentration</measure>
    <time_frame>Baseline</time_frame>
    <description>Diabetes control</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting Hemoglobin A1c concentration</measure>
    <time_frame>Baseline</time_frame>
    <description>Diabetes control</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin concentration</measure>
    <time_frame>Baseline</time_frame>
    <description>Hormone involved in bone metabolism</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum 25-hydroxyvitamin D concentration</measure>
    <time_frame>Baseline</time_frame>
    <description>Hormone involved in bone metabolism</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parathormone concentration</measure>
    <time_frame>Baseline</time_frame>
    <description>Hormone involved in bone metabolism</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estradiol concentration</measure>
    <time_frame>Baseline</time_frame>
    <description>Hormone involved in bone metabolism</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin like growth factor-1 concentration</measure>
    <time_frame>Baseline</time_frame>
    <description>Hormone involved in bone metabolism</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sclerostin concentration</measure>
    <time_frame>Baseline</time_frame>
    <description>Hormone involved in bone metabolism</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adiponectin concentration</measure>
    <time_frame>Baseline</time_frame>
    <description>Hormone involved in bone metabolism</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Leptin concentration</measure>
    <time_frame>Baseline</time_frame>
    <description>Hormone involved in bone metabolism</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body composition measured as visceral and subcutaneous adipose tissue</measure>
    <time_frame>Baseline</time_frame>
    <description>Measured by computed tomography (CT)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body composition measured by fat and lean mass</measure>
    <time_frame>Baseline</time_frame>
    <description>Measured using dual-energy X-ray absorptiometry (DXA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone marrow adiposity</measure>
    <time_frame>Baseline</time_frame>
    <description>Measured by computed tomography (CT)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Upper extremity muscle strength measured by grip force in kg</measure>
    <time_frame>Baseline</time_frame>
    <description>Measured using Jamar Hydraulic Hand Dynamometer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lower extremity muscle strength measured by peak torque generated by knee extension</measure>
    <time_frame>Baseline</time_frame>
    <description>Measured using Biodex isokinetic dynamometer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional mobility measured by time that a person takes to rise from a chair, walk three meters, turn around, walk back to the chair, and sit down.</measure>
    <time_frame>Baseline</time_frame>
    <description>Measured using Timed Up and Go test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional exercise capacity measured by total distance ambulated during a 6 minute time period</measure>
    <time_frame>Baseline</time_frame>
    <description>Measured using Six Minute Walk Test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Self-reported physical activity measured in metabolic equivalents (MET)</measure>
    <time_frame>Baseline</time_frame>
    <description>Measured using the International Physical Activity Questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cutaneous Advanced glycation end products (AGEs) measurement</measure>
    <time_frame>Baseline</time_frame>
    <description>Measured by measured by AGE Reader</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physical activity measured by total activity and time spent in different intensities of exercise measured over 7 consecutive days</measure>
    <time_frame>Baseline</time_frame>
    <description>Actigraph GT3X+ Accelerometer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional balance score obtained using multidimensional balance assessment. Higher scores indicate better balance abilities</measure>
    <time_frame>Baseline</time_frame>
    <description>Fullerton Advanced Balance (FAB) Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physical health</measure>
    <time_frame>Baseline</time_frame>
    <description>SF-12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Community Participation Restriction</measure>
    <time_frame>Baseline</time_frame>
    <description>Life-space mobility assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-related quality of life</measure>
    <time_frame>Baseline</time_frame>
    <description>How are you today? Visual analogue scale</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">40</enrollment>
  <condition>Diabetes Mellitus</condition>
  <condition>Diabetes Mellitus, Type 2</condition>
  <condition>Obesity</condition>
  <condition>Body Weight</condition>
  <condition>Bone Diseases, Metabolic</condition>
  <condition>Fractures, Bone</condition>
  <condition>Osteoporotic Fractures</condition>
  <condition>Osteoporosis</condition>
  <condition>Quality of Life</condition>
  <condition>Fall</condition>
  <condition>Musculoskeletal Diseases</condition>
  <arm_group>
    <arm_group_label>Diabetic</arm_group_label>
    <description>20 men and women with type 2 diabetes and obesity</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-diabetic</arm_group_label>
    <description>20 normoglycemic men and women with obesity matched for age and sex with diabetic group</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        This is a multi-center, cross-sectional, observational study comprising of two groups of&#xD;
        participants with obesity either with or without diabetes (n=20/group). The diabetic groups&#xD;
        will include 20 adult men and women with obesity and type 2 diabetes, and the non-diabetic&#xD;
        group will consist of 20 age- and sex- matched individuals with obesity and normoglycemia.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        A) Diabetic group&#xD;
&#xD;
          -  BMI &gt;=35 kg/m2&#xD;
&#xD;
          -  Clinical diagnosis of type 2 diabetes&#xD;
&#xD;
          -  Use of oral hypoglycemic agents or insulin or 2 of the following tests confirming type&#xD;
             2 diabetes: HbA1c &gt;=6.5%; fasting glucose &gt;=7.0 mM; 2-h glucose post 75g oral glucose&#xD;
             tolerance test (OGTT) &gt;=11.1 mM)&#xD;
&#xD;
        B) Non-diabetic group:&#xD;
&#xD;
          -  BMI &gt;=35 kg/m2&#xD;
&#xD;
          -  Normoglycemia (HgbA1c &lt;5.7% and Fasting glucose &lt;5.6 nM)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  BMI &gt;60 kg/m2&#xD;
&#xD;
          -  Clinical diagnosis of type 1 diabetes&#xD;
&#xD;
          -  Disease (e.g. uncontrolled thyroid disease, malabsorptive or overt inflammatory&#xD;
             disorder, metabolic bone disease, creatinine clearance &lt;60 ml/min)&#xD;
&#xD;
          -  Medication (e.g. gluccocorticoids, anti-epileptic drugs, osteoporosis therapy and&#xD;
             thiazolidinediones) affecting bone metabolism&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  History of oesophageal, gastric, digestive or bariatric surgery&#xD;
&#xD;
          -  Prosthesis that could interfere with interpretation of imaging data&#xD;
&#xD;
          -  Chronic severe condition or illness precluding from participation in the project.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Research Institute of the McGill University Health Centre</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H3H 2R9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre de recherche de l'IUCPQ</name>
      <address>
        <city>Québec</city>
        <zip>G1V 4G5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>September 10, 2019</study_first_submitted>
  <study_first_submitted_qc>September 13, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 18, 2019</study_first_posted>
  <last_update_submitted>August 30, 2021</last_update_submitted>
  <last_update_submitted_qc>August 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>McGill University Health Centre/Research Institute of the McGill University Health Centre</investigator_affiliation>
    <investigator_full_name>Suzanne Morin</investigator_full_name>
    <investigator_title>Clinician Researcher</investigator_title>
  </responsible_party>
  <keyword>Advanced glycation end products</keyword>
  <keyword>Advanced imaging</keyword>
  <keyword>Mobility</keyword>
  <keyword>Strength</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
    <mesh_term>Bone Diseases</mesh_term>
    <mesh_term>Musculoskeletal Diseases</mesh_term>
    <mesh_term>Bone Diseases, Metabolic</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Obesity</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Metabolic Diseases</mesh_term>
    <mesh_term>Body Weight</mesh_term>
    <mesh_term>Fractures, Bone</mesh_term>
    <mesh_term>Osteoporotic Fractures</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

